Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eric F Kong

Characterization of Tumor Mutation Burden, PD-L1 and DNA Repair Genes to Assess Relationship to Immune Checkpoint Inhibitors Response in Metastatic Renal Cell Carcinoma

Journal for ImmunoTherapy of Cancer

English

Related publications

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

English

PD-L1 Expression in Basaloid Squamous Cell Lung Carcinoma: Relationship to PD-1+ and CD8+ Tumor-Infiltrating T Cells and Outcome

English

Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Clinical Genitourinary Cancer

Oncology

Urology

2019

English

Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD‑L1: A Case Report

Molecular and Clinical Oncology

Cancer Research

Oncology

2017

English

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer

English

P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients With Metastatic Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

First-Line Immune Checkpoint Therapy in Metastatic Squamous Cell Lung Cancer Harboring Both EGFR Mutation and High Expression of PD-L1: A Case Report

English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology

English

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma

Expert Review of Clinical Pharmacology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eric F Kong

Characterization of Tumor Mutation Burden, PD-L1 and DNA Repair Genes to Assess Relationship to Immune Checkpoint Inhibitors Response in Metastatic Renal Cell Carcinoma

Related publications

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

PD-L1 Expression in Basaloid Squamous Cell Lung Carcinoma: Relationship to PD-1+ and CD8+ Tumor-Infiltrating T Cells and Outcome

Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD‑L1: A Case Report

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients With Metastatic Non-Small-Cell Lung Cancer

First-Line Immune Checkpoint Therapy in Metastatic Squamous Cell Lung Cancer Harboring Both EGFR Mutation and High Expression of PD-L1: A Case Report

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma